Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment
- 1 April 2001
- journal article
- clinical trial
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 24 (4) , 246-252
- https://doi.org/10.1007/bf03343854
Abstract
After prolonged treatment (76.4±10 and 70.1±12.3 months, respectively) (mean± SE) with testosterone enanthate (250 mg im every 3 weeks), bone mineral density (BMD) and bone metabolism were evaluated in 12 patients (aged 29.3±1.4 yr) affected by idiopathic hypogonadotropic hypogonadism (IHH), in 8 patients (29.6±2.6 yr) affected by Klinefelter’s syndrome (KS), and in 10 healthy men (30.6±1.7 yr) matched according to age and BMI. Spinal BMD in IHH was significantly lower than in controls (0.804±0.04 vs 1.080±0.01 g/cm2; pKeywords
This publication has 23 references indexed in Scilit:
- Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a ManNew England Journal of Medicine, 1994
- Loss of bone mass in patients with Klinefelter's syndrome despite sufficient testosterone replacementOsteoporosis International, 1993
- Risk factors for osteoporosis in menClinical Endocrinology, 1993
- Osteoporosis and Klinefelter's syndromeClinical Endocrinology, 1992
- Osteoporosis in MenMedicine, 1990
- WHICH TESTOSTERONE REPLACEMENT THERAPY?Clinical Endocrinology, 1984
- Risk factors for spinal osteoporosis in menThe American Journal of Medicine, 1983
- Testosterone and Bone Loss in Klinefelter SyndromeHormone and Metabolic Research, 1983
- Steroid hormones, ageing and boneClinics in Endocrinology and Metabolism, 1981
- Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal maleCalcified Tissue International, 1978